Navigation Links
Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
Date:12/13/2012

STATEMENT

This press release includes forward-looking statements regarding Isis' collaboration with GlaxoSmithKline, the discovery, development and potential of drugs for severe and rare diseases, and the development, activity, therapeutic potential and safety of ISIS-TTRRx. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
2. CVS Caremark Provides Strong Growth Outlook for 2013 and Beyond, Announces 38%Dividend Increase and Outlines Strategic Growth Framework
3. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
4. Mylan Announces Pricing of Senior Notes
5. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
6. Alere Inc. Announces Hiring of Namal Nawana as Chief Operating Officer
7. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
8. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
9. River Vision Announces Completion of $17 million Series A Financing
10. Winner Medical Announces Closing of Going Private Transaction
11. Alere Inc. Announces Early Results of its Tender Offer and Consent Solicitation for Any and All of its 7.875% Senior Notes due 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... YORK , September 23, 2014 ... pioneer in computer-aided dysmorphology analysis will exhibit at the ... Diego, CA. FDNA will present the latest ... and reference solution, using facial analysis technology. Face2Gene facilitates ... of human malformations from facial photos. The ...
(Date:9/23/2014)... , Sept. 23, 2014  Medela announced today ... Biomedical Company (ABC), assigning Medela as the exclusive distributor ... known as the Medela Enteral Feeding Pump. Through this ... help NICU parents and healthcare professionals by offering a ... Medela Enteral Feeding Pump is integral to the delivery ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that it has appointed ... President of Biopharmaceutical Development.  Dr. Arumugham has over ... and development (R&D) in the areas of formulation ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 2Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 3Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development 4
... HbA1c reductions seen in ischemic patients with ... diabetes in earlier clinical trials -, ... ) announced today that data from a prospectively identified,analysis of ... (ranolazine extended-release tablets) significantly reduced,hemoglobin A1c (HbA1c), increased the number ...
... Cleveland Clinic Researchers Highlight the Need For More Women to ... ... Cleveland Clinic,researchers have recently found that women remain a significant ... and Blood Institute (NHLBI). Lead Author, Esther S.H. Kim, ...
Cached Medicine Technology:CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36 2CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36 3CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36 4Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 2
(Date:9/23/2014)... September 23, 2014 With summer at ... in spirit and weather), organic food manufacturing company Earth ... month centered on sweet treats for the whole family. ... bite-sized candies by the handful in celebration of the ... recent years these festivities come with an increasing degree ...
(Date:9/23/2014)... IL (PRWEB) September 23, 2014 ... solutions, has expanded its MedMaster™ M4 product line ... luminaire extends the M4 product line – currently ... LED options – providing more flexibility when designing ... the MedMaster M4 Series include:, •Three ...
(Date:9/23/2014)... On September 20- 21, 2014, people ... two days of Trivedi Retreat ‘Consciousness is Power’, online ... the Energy Transmissions from Mahendra Trivedi and Trivedi Masters™ ... people enjoyed the In-person, group and live Energy Transmissions ... Trivedi and Trivedi Master™ Alice Branton, where, they described ...
(Date:9/23/2014)... (HealthDay News) -- Pregnant women appear to have an ... a new study. And this strong immune ... from the flu than other healthy adults. The reason: ... immune system responding to the virus, the researchers said. ... that pregnancy weakens the immune system to keep it ...
(Date:9/23/2014)... On September 8th, the company XenOPAT SL, a spin-off ... Catalan Institute of Oncology (ICO) was established with the ... to the service combating cancer with two main branches: ... of personalized cancer treatments. , Orthotopic models and ... the use of orthotopic models (orthoxenograft) mouse by implantation ...
Breaking Medicine News(10 mins):Health News:Righteously Raw Chocolates Promote Healthy, Fun Snacking this Fall Season 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 2Health News:Kenall Expands MedMaster™ M4 Surgical Suite Product Portfolio with New 1'×4' Option 3Health News:The Trivedi Retreat ‘Consciousness is Power’ was Huge Success 2Health News:The Trivedi Retreat ‘Consciousness is Power’ was Huge Success 3Health News:Study Suggests Why Pregnant Women Get Sicker From Flu 2Health News:Study Suggests Why Pregnant Women Get Sicker From Flu 3Health News:XenOPAT, mouse models for personalized cancer treatment 2
... ... ... ... ...
... ... ... ... ...
... ... ... , ... TULSA, Okla. , Feb. 19 U.S. ...
... more fumes that are likely carcinogenic than with electric ranges ... hot stove -- make that a hot gas ... cancer. , Researchers in Norway have found that cooking with ... , But, in a report published online Feb. 17 in ...
... (P4P) programs are payment models that reward workers for ... the healthcare setting, P4P programs use a variety of ... fee differentials and bonuses. A new study ... that P4P programs appear to be effective in incentivizing ...
... ... momentum created by local communities and the NGO Tostan to end the practice by 2015 ... Dakar, Senegal (PRWEB) February ... cutting (FGC) which has seen thousands of communities in Senegal join its ranks in recent ...
Cached Medicine News:Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 2Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 3Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 4Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 2Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 3Health News:Gas Cooking Might Up Your Cancer Risk 2Health News:Gas Cooking Might Up Your Cancer Risk 3Health News:Senegal: Total End of Female Genital Cutting Now in Sight 2
... The 1700 Series Outpatient Surgical Table ... standards as Skytron's other specialty and general ... their key features such as 180-degree top ... extremely durable side rails will accommodate a ...
23" Top Slide with Full Table Functions for Every Procedure...
... operating table for any application. The ... unlimited C-arm access. High stability guarantees ... and cardiovascular procedures. An extension device ... can easily be attached for orthopedic ...
As with all Eschmann products the T20 operating table was designed with 'Simplicity and Intuitiveness' in mind, having drawn influences from leading clinicians of various levels from across the globe...
Medicine Products: